吉西他滨联合奈达铂化疗治疗50例鼻咽癌肺转移的临床疗效分析

摘要

Objective:To observe and analyze the curative effect of Gemcitabine combined with Nedaplatin chemotherapy on treating 50 cases of lung metastases transform nasopharyngeal carcinoma.Method:90 patients were divided into Gemcitabine combined with Nedaplatin chemotherapy group(GN group) and Cisplatin,5-fluorouracil combined with Docetaxel chemotherapy group(PTF group),the clinical effect and adverse reactions of two groups were retrospective analyzed.Result:The effective rate of GN group was 70.0%,there was obviously improved compared with the PTF group(45.0%),the difference was statistically significant(P<0.05).The two group’s disease control rates were 94.0% and 80.0%,with no significant difference(P>0.05).GN group’s leukopenia and thrombocytopenia grade Ⅲ-Ⅳ incidence rate were lower than than those of PTF group(P<0.05).Conclusion:Gemcitabine combined with Nedaplatin chemotherapy can further improve the prognosis of patients with nasopharyngeal carcinoma with lung metastasis,chemotherapy related toxicity was significantly lower,and it is worthy of clinical application.%目的：观察分析吉西他滨联合奈达铂化疗治疗鼻咽癌肺转移的临床疗效。方法：90例纳入患者根据其接受的化疗方案分为吉西他滨联合奈达铂化疗组(GN组)、顺铂、5-氟尿嘧啶联合多西他赛化疗组(PTF组)，回顾性分析两组的临床疗效及毒副反应发生情况。结果：GN组治疗有效率为70.0%，较PTF组有明显提高(45.0%)，差异有统计学意义(P<0.05)；两组疾病控制率分别为94.0%、80.0%，差异无统计学意义(P>0.05)。GN组白细胞减少、血小板减少Ⅲ~Ⅳ级发生率均较PTF组降低(P<0.05)。结论：吉西他滨联合奈达铂化疗可进一步提高鼻咽癌肺转移患者预后，化疗相关毒性明显降低，值得临床推广应用。